Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

Fri, 04 Sep 2026 09:15:00 -0400

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today announced that Lea Knight, chief financial officer, and Michael McBreen, chief commercial officer, will present at the 2026 Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 2:15 p.m. ET. Stuart Essig, chairman and chief executive officer, will present at the 2026 Morgan Stanley Healthcare Conference on Tuesday, September 15, 2026, at 4:05 p.m. ET.

A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

Fri, 04 Sep 2026 09:15:00 -0400

A live webcast of the presentations will be available on the Integra LifeSciences investor relations website under

Form SCHEDULE 13G/A INTEGRA LIFESCIENCES Filed by: PARADIGM CAPITAL MANAGEMENT INC/NY

Thu, 13 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260813/26922274.html

Form SCHEDULE 13G/A INTEGRA LIFESCIENCES Filed by: PARADIGM CAPITAL MANAGEMENT INC/NY

Thu, 13 Aug 2026 16:44:00 -0400

si-local-file:///var/storage/secattach/20260813/26922274.html

Form SCHEDULE 13G INTEGRA LIFESCIENCES Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:25:00 -0400

si-local-file:///var/storage/secattach/20260731/26848802.html

Form SCHEDULE 13G INTEGRA LIFESCIENCES Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Fri, 31 Jul 2026 11:25:00 -0400

si-local-file:///var/storage/secattach/20260731/26848802.html

Integra LifeSciences (IART) PT Lowered to $18 at BMO Capital

Thu, 30 Jul 2026 09:04:23 -0400

BMO Capital analyst Vik Chopra lowered the price target on Integra LifeSciences (NASDAQ: IART) to $18.00 (from $19.00) while maintaining a Market Perform rating.

Integra LifeSciences (IART) PT Raised to $18 at Wells Fargo

Thu, 30 Jul 2026 08:30:49 -0400

Wells Fargo analyst Larry Biegelsen raised the price target on Integra LifeSciences (NASDAQ: IART) to $18.00 (from $15.00) while maintaining a Equal Weight rating.

Form 10-Q INTEGRA LIFESCIENCES For: Jun 30

Wed, 29 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260729/26834768.html

Form 10-Q INTEGRA LIFESCIENCES For: Jun 30

Wed, 29 Jul 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260729/26834768.html

Integra LifeSciences (IART) Tops Q2 EPS by 8c ; Offers Guidance

Wed, 29 Jul 2026 06:24:43 -0400

Integra LifeSciences (NASDAQ: IART) reported Q2 EPS of $0.56, $0.08 better than the analyst estimate of $0.48. Revenue for the quarter came in at $418.8 million versus the consensus estimate of $417.62 million.

GUIDANCE:

Integra LifeSciences sees FY2026 EPS of $2.40-$2.50, versus the consensus of $2.45. Integra LifeSciences sees FY2026 revenue of $1.65-1.69 billion, versus the consensus of $1.67 billion.

Integra LifeSciences sees Q3 2026 EPS of $0.53-$0.61, versus the consensus of $0.57. Integra LifeSciences sees Q3 2026 revenue of $410-425 million, versus the consensus of $417.4 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

Integra LifeSciences (IART) Tops Q2 EPS by 8c ; Offers Guidance

Wed, 29 Jul 2026 06:24:43 -0400

GUIDANCE:

Integra LifeSciences sees FY2026 EPS of $2.40-$2.50, versus the consensus of $2.45. Integra LifeSciences sees FY2026 revenue of $1.65-1.69 billion, versus the consensus of $1.67 billion.

Integra LifeSciences sees Q3 2026 EPS of $0.53-$0.61, versus the consensus of $0.57. Integra LifeSciences sees Q3 2026 revenue of $410-425 million, versus the consensus of $417.4 million.

For earnings history and earnings-related data on Integra LifeSciences (IART) click here.

Form 8-K INTEGRA LIFESCIENCES For: Jul 29

Wed, 29 Jul 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26829865.html

Form 8-K INTEGRA LIFESCIENCES For: Jul 29

Wed, 29 Jul 2026 06:15:00 -0400

si-local-file:///var/storage/secattach/20260729/26829865.html

Integra LifeSciences Reports Second Quarter 2026 Financial Results

Wed, 29 Jul 2026 06:00:00 -0400

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.

Second Quarter 2026 Highlights

Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year.
Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.
Integra LifeSciences Reports Second Quarter 2026 Financial Results

Wed, 29 Jul 2026 06:00:00 -0400

PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.

Second Quarter 2026 Highlights
- Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
- Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year.
- Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.
  Integra LifeSciences Reports Second Quarter 2026 Financial Results
  
  Wed, 29 Jul 2026 06:00:00 -0400
  
  PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
  
  Second Quarter 2026 Highlights
  - Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
  - Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year.
  - Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.
    
    Integra LifeSciences Reports Second Quarter 2026 Financial Results
    
    Wed, 29 Jul 2026 06:00:00 -0400
    
    PRINCETON, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2026.
    
    Second Quarter 2026 Highlights
    
    Second quarter revenues of $418.8 million increased 0.8% on a reported basis and 0.7% on an organic basis compared to the prior year.
    
    Second quarter GAAP earnings per diluted share of $0.06, compared to $(6.31) in the prior year.
    
    Adjusted earnings per diluted share of $0.56, compared to $0.45 in the prior year.
    
    UBS starts medtech coverage, favors Intuitive Surgical and Enovis
    
    Tue, 28 Jul 2026 09:22:16 -0400
    
    Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.
    
    The brokerage said the sector offers a mix of opportunities tied to innovation, procedure growth and operational recovery, but warned that not all companies are equally positioned to capitalize on those trends. UBS assigned Buy ratings to Intuitive Surgical and Enovis, a Sell rating to Inspire Medical and a Neutral rating
    
    UBS starts medtech coverage, favors Intuitive Surgical and Enovis
    
    Tue, 28 Jul 2026 09:22:16 -0400
    
    Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.
    
    The brokerage said the sector offers a mix of opportunities tied to innovation, procedure growth and operational recovery, but warned that not all companies are equally positioned to capitalize on those trends. UBS assigned Buy ratings to Intuitive Surgical and Enovis, a Sell rating to Inspire Medical and a Neutral rating
    
    UBS starts medtech coverage, favors Intuitive Surgical and Enovis
    
    Tue, 28 Jul 2026 09:22:16 -0400
    
    Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.
    
    The brokerage said the sector offers a mix of opportunities tied to innovation, procedure growth and operational recovery, but warned that not all companies are equally positioned to capitalize on those trends. UBS assigned Buy ratings to Intuitive Surgical and Enovis, a Sell rating to Inspire Medical and a Neutral rating
    
    UBS starts medtech coverage, favors Intuitive Surgical and Enovis
    
    Tue, 28 Jul 2026 09:22:16 -0400
    
    Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.
    
    The brokerage said the sector offers a mix of opportunities tied to innovation, procedure growth and operational recovery, but warned that not all companies are equally positioned to capitalize on those trends. UBS assigned Buy ratings to Intuitive Surgical and Enovis, a Sell rating to Inspire Medical and a Neutral rating
    
    UBS starts medtech coverage, favors Intuitive Surgical and Enovis
    
    Tue, 28 Jul 2026 09:22:16 -0400
    
    Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.
    
    The brokerage said the sector offers a mix of opportunities tied to innovation, procedure growth and operational recovery, but warned that not all companies are equally positioned to capitalize on those trends. UBS assigned Buy ratings to Intuitive Surgical and Enovis, a Sell rating to Inspire Medical and a Neutral rating
    
    UBS starts medtech coverage, favors Intuitive Surgical and Enovis
    
    Tue, 28 Jul 2026 09:22:16 -0400
    
    Investing.com -- UBS initiated coverage on four U.S. medical technology companies on Monday, taking a bullish stance on robotic surgery specialist Intuitive Surgical and orthopedic products maker Enovis, while adopting a more cautious outlook on sleep apnea device manufacturer Inspire Medical Systems and a neutral view on Integra LifeSciences.
    
    The brokerage said the sector offers a mix of opportunities tied to innovation, procedure growth and operational recovery, but warned that not all companies are equally positioned to capitalize on those trends. UBS assigned Buy ratings to Intuitive Surgical and Enovis, a Sell rating to Inspire Medical and a Neutral rating
    
    UBS Starts Integra LifeSciences (IART) at Neutral
    
    Tue, 28 Jul 2026 06:32:35 -0400
    (Updated - July 28, 2026 6:32 AM EDT)
    UBS analyst Patrick Wood initiates coverage on Integra LifeSciences (NASDAQ: IART) with a Neutral rating and a price target of $19.00.
    The analyst comments "We initiate coverage of IART with a Neutral rating and a $19 price target. Despite recent regulatory and operational difficulties and a historically high leverage profile, IART's fundamental building blocks are relatively sound: IART is a category leader across end- markets that are themselves structural MSD growers, so the Street's expectations on organic numbers (+2-3% from 3Q26 onward) look feasible, in our eyes, and likely don't require further share gains

StreetInsider.com News Articles

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

Integra LifeSciences to Present at the 2026 Wells Fargo Healthcare Conference and the 2026 Morgan Stanley Healthcare Conference

Form SCHEDULE 13G/A INTEGRA LIFESCIENCES Filed by: PARADIGM CAPITAL MANAGEMENT INC/NY

Form SCHEDULE 13G/A INTEGRA LIFESCIENCES Filed by: PARADIGM CAPITAL MANAGEMENT INC/NY

Form SCHEDULE 13G INTEGRA LIFESCIENCES Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Form SCHEDULE 13G INTEGRA LIFESCIENCES Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC

Integra LifeSciences (IART) PT Lowered to $18 at BMO Capital

Integra LifeSciences (IART) PT Raised to $18 at Wells Fargo

Form 10-Q INTEGRA LIFESCIENCES For: Jun 30

Form 10-Q INTEGRA LIFESCIENCES For: Jun 30

Integra LifeSciences (IART) Tops Q2 EPS by 8c ; Offers Guidance

Integra LifeSciences (IART) Tops Q2 EPS by 8c ; Offers Guidance

Form 8-K INTEGRA LIFESCIENCES For: Jul 29

Form 8-K INTEGRA LIFESCIENCES For: Jul 29

Integra LifeSciences Reports Second Quarter 2026 Financial Results

Integra LifeSciences Reports Second Quarter 2026 Financial Results

Integra LifeSciences Reports Second Quarter 2026 Financial Results

Integra LifeSciences Reports Second Quarter 2026 Financial Results

UBS starts medtech coverage, favors Intuitive Surgical and Enovis

UBS starts medtech coverage, favors Intuitive Surgical and Enovis

UBS starts medtech coverage, favors Intuitive Surgical and Enovis

UBS starts medtech coverage, favors Intuitive Surgical and Enovis

UBS starts medtech coverage, favors Intuitive Surgical and Enovis

UBS starts medtech coverage, favors Intuitive Surgical and Enovis

UBS Starts Integra LifeSciences (IART) at Neutral